India Should Play Up R&D Strengths But Build "China-like" Infrastructure - BIO India Conference
This article was originally published in PharmAsia News
Executive Summary
HYDERABAD - Indian companies are more entrepreneurially driven than their Chinese counterparts, and although a noticeable switch in mindset toward innovation is welcomed, the government needs to participate more in building infrastructure to raise confidence levels for global companies to funnel more research work to India, multinational companies urged
You may also be interested in...
India Battles “Specious” Quality Allegations, Demurs on PIC/S
India’s new Department of Pharmaceuticals Secretary Aradhana Johri said India will challenge the “specious issue” of quality that she says is raised in other countries to simply exclude the Indian industry. Meanwhile, the department continues to resist the entreaties of India’s domestic pharmaceutical manufacturers to seek membership in PIC/S, which would require strengthening its inspectorate in ways that would pressure them to meet international standards.
In Balancing Competing Interests, India’s New Pharma Secretary Likens Her Role To A Trapeze Artist
India’s new Department of Pharmaceuticals Secretary Aradhana Johri compared her role to that of a trapeze artist to balance rival interests, like ensuring affordable medicines while safeguarding the industry. But on the issue of exports, Johri said India will strongly negotiate against the “specious issue” of quality that she says is raised in other countries to simply exclude the Indian industry.
In API Battle, China Chips Away At India’s Share; India Calls For Policy Safeguards
China is becoming a serious threat to India’s indigenous API manufacturers, as India seeks policy safeguards such as anti-dumping duties and stricter inspections on Chinese imports.